On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of increased funding for domestic HIV and hepatitis programs in the FY 2021 Labor, HHS spending bill…
HIV+Hepatitis Policy Institute outlines FY2021 appropriations priorities
The HIV+Hepatitis Policy Institute appreciates the work the Senate has been doing over the last several months responding to the COVID-19 pandemic. We thank you for your continued attention to this crisis, particularly as it affects our nation’s public health infrastructure. We are very appreciative…
Testimony for the Record to the House Appropriations Labor HHS Subcommittee (FY 2021)
On behalf of the HIV+HEP Policy Institute, we respectfully submit this testimony in support of increased funding for domestic HIV and hepatitis programs in the FY 2021 Labor, HHS spending bill…
Cost-sharing for prescription drugs; Comments on 2021 notice of benefit and payment parameters proposed rule
The HIV + Hepatitis Policy Institute, a national, non-profit organization whose mission is to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions, is pleased to submit comments on the proposed Notice of Benefit…
Comments on transparency in coverage proposed rule
The HIV+Hepatitis Policy Institute, a new national, non-profit organization whose mission is to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions, is pleased to submit comments on the proposed rule to increase price transparency…